No connection

Search Results

AQST vs KMDA

AQST
Aquestive Therapeutics, Inc.
BEARISH
Price
$4.02
Market Cap
$490.5M
Sector
Healthcare
AI Confidence
85%
KMDA
Kamada Ltd.
NEUTRAL
Price
$8.49
Market Cap
$490.9M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
AQST
--
KMDA
24.26
Forward P/E
AQST
-6.93
KMDA
14.31
P/B Ratio
AQST
-14.57
KMDA
1.82
P/S Ratio
AQST
11.01
KMDA
2.72
EV/EBITDA
AQST
-5.84
KMDA
10.78

Profitability

Gross Margin
AQST
58.34%
KMDA
42.34%
Operating Margin
AQST
-221.58%
KMDA
7.95%
Profit Margin
AQST
-188.09%
KMDA
11.19%
ROE
AQST
--
KMDA
7.64%
ROA
AQST
-33.92%
KMDA
4.37%

Growth

Revenue Growth
AQST
9.7%
KMDA
14.5%
Earnings Growth
AQST
--
KMDA
-14.1%

Financial Health

Debt/Equity
AQST
--
KMDA
0.04
Current Ratio
AQST
3.13
KMDA
4.07
Quick Ratio
AQST
2.92
KMDA
2.2

Dividends

Dividend Yield
AQST
--
KMDA
2.94%
Payout Ratio
AQST
0.0%
KMDA
0.0%

AI Verdict

AQST BEARISH

AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.

Strengths
Gross margin of 58.34% suggests strong pricing power or cost control in product manufacturing
Revenue growth of 9.70% YoY indicates some market traction despite losses
Current ratio of 3.13 and quick ratio of 2.92 reflect strong short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative ROA (-33.92%) and ROE (N/A) indicate capital is not being deployed effectively
Insider selling by CEO, CFO, and COO totaling $1.86M in six months is a major red flag
KMDA NEUTRAL

KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.

Strengths
Exceptional liquidity with a Current Ratio of 4.07
Negligible leverage with Debt/Equity at 0.04
Strong PEG ratio (0.63) indicating potential growth undervaluation
Risks
Significant disconnect between current price ($8.49) and Intrinsic Value ($2.45)
Negative earnings growth (-14.10% YoY) despite revenue gains
Bearish technical trend (0/100 score)

Compare Another Pair

AQST vs KMDA: Head-to-Head Comparison

This page compares Aquestive Therapeutics, Inc. (AQST) and Kamada Ltd. (KMDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile